Recent Member Publications

LenihanD

Dr. Daniel Lenihan, MD

Prospective Observation of Cardiac Safety with Proteasome Inhibitor

FROM THE JOURNAL OF CLINICAL ONCOLOGY


Cardiovascular (CV) adverse events were common in patients receiving proteasome inhibitor therapy for relapsed multiple myeloma, especially with carfilzomib-based therapy, according to results from the PROTECT study.
While prior studies have shown an increased risk for CV toxicities with proteasome inhibitor therapy, detailed descriptions of the events and risk factors have been lacking. “Furthermore, there is no validated protocol to help determine which patients are at highest risk of CV toxicity during therapy, nor is there management guidance for patients who experience a [CV adverse event],” wrote Robert F. Cornell, MD, of Vanderbilt University, Nashville, Tenn., and colleagues in the Journal of Clinical Oncology.

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

By Kathleen W. Zhang, MD,a Keith E. Stockerl-Goldstein, MD,b Daniel J. Lenihan, MDa

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

Download Broucher [732.12 KB]

 

Florida Inter-Specialty Collaborative Project to Improve Cardio-Oncology Awareness and Identify Existing Knowledge Gaps

Cancer and cardiovascular disease are 2 primary causes of morbidity and mortality in the United States (1). In addition to the physical burden of disease, there is an emotional and financial toll on patients, family members, and the health care system at large (2). The success of novel cancer therapies has resulted in significantly improved disease-free and progression-free survival for many cancers; however, many conventional and newer cancer treatments, including radiation therapy, chemotherapeutic agents, targeted therapies, and immunotherapies, are also associated with an increased risk of a number of adverse effects, including cardiovascular toxicity (3).

Journal of Clinical Medicine

Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology.

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

Download Broucher [1.09 MB]

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

Download Broucher [336.76 KB]

Implementing a Cardiooncology Center of Excellence Nuts and Bolts, Including Coding and Billing

Cardio-oncology is an evolving subspecialty of cardiology that deals with the acute and long-term care of cancer patients as well as cancer survivors. It has developed in concordance with the advances in oncology that have vastly increased the armamentarium of therapies for cancer patients and the subsequent cardiac toxicities that have emerged, both during therapy and sometimes decades later as cancer-related cardiac
dysfunction.1 The enormous complexity of the cancer treatments, with the myriad cardiac issues that can arise during therapy, mandate a collaboration that is diverse, knowledgeable, streamlined, cost-efficient, and, most of all, able to navigate patients through an increasingly
complicated health care system in a timely fashion.

JAMA | Original Investigation254

Ariane Macedo, MD

“Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19 A Randomized Clinical Trial”

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab

Download Broucher [450.54 KB]

Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin.

Sebastian Szmit, MD, PhD, Michal Wilk, et.al.


Read More

Heart disease and breast cancer

Dr YT Singh explains that heart disease is the reason why breast cancer patients due to receive cardiotoxic therapy need a cardiovascular assessment before, during and after cancer treatment..

Read More
BMC

Perspectives on the COVID-19 pandemic impact on cardio-oncology

Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care in this setting has not been formally evaluated.

Read more